 Paco Herson
Concepts (495)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Ischemia | 36 | 2025 | 343 | 9.840 |
Why?
| | TRPM Cation Channels | 12 | 2024 | 74 | 5.300 |
Why?
| | Heart Arrest | 25 | 2025 | 358 | 5.290 |
Why?
| | Hippocampus | 23 | 2025 | 911 | 3.360 |
Why?
| | Stroke | 22 | 2025 | 1136 | 3.340 |
Why?
| | Neurons | 31 | 2023 | 1594 | 3.020 |
Why?
| | Neuroprotective Agents | 16 | 2020 | 134 | 3.010 |
Why?
| | Cardiopulmonary Resuscitation | 16 | 2025 | 265 | 2.740 |
Why?
| | Sex Characteristics | 16 | 2024 | 767 | 2.290 |
Why?
| | Cell Death | 16 | 2021 | 373 | 2.050 |
Why?
| | Purkinje Cells | 7 | 2019 | 68 | 2.010 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 7 | 2024 | 185 | 1.780 |
Why?
| | Recovery of Function | 6 | 2025 | 666 | 1.730 |
Why?
| | Mice, Inbred C57BL | 48 | 2025 | 5770 | 1.600 |
Why?
| | CA1 Region, Hippocampal | 7 | 2024 | 52 | 1.570 |
Why?
| | Animals | 97 | 2025 | 37129 | 1.360 |
Why?
| | Gonadal Steroid Hormones | 5 | 2025 | 138 | 1.360 |
Why?
| | Mice | 64 | 2025 | 17761 | 1.330 |
Why?
| | Androgens | 8 | 2014 | 186 | 1.330 |
Why?
| | Long-Term Potentiation | 8 | 2025 | 198 | 1.200 |
Why?
| | Ischemia | 5 | 2022 | 411 | 1.170 |
Why?
| | Neuroprotection | 3 | 2020 | 42 | 1.130 |
Why?
| | Receptors, GABA-A | 5 | 2024 | 139 | 1.110 |
Why?
| | Disease Models, Animal | 24 | 2022 | 4308 | 1.090 |
Why?
| | Peptide Fragments | 2 | 2021 | 691 | 1.020 |
Why?
| | Signal Transduction | 11 | 2024 | 5065 | 0.990 |
Why?
| | Infarction, Middle Cerebral Artery | 12 | 2023 | 42 | 0.950 |
Why?
| | Poly(ADP-ribose) Polymerases | 4 | 2013 | 98 | 0.910 |
Why?
| | Reperfusion Injury | 8 | 2020 | 278 | 0.890 |
Why?
| | Hypothermia, Induced | 3 | 2016 | 84 | 0.880 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 5 | 2014 | 12 | 0.840 |
Why?
| | Male | 71 | 2025 | 68035 | 0.830 |
Why?
| | Calcium | 10 | 2022 | 1183 | 0.810 |
Why?
| | Brain Injuries, Traumatic | 4 | 2023 | 372 | 0.770 |
Why?
| | Brain | 13 | 2024 | 2748 | 0.750 |
Why?
| | Brain Injuries | 5 | 2021 | 495 | 0.740 |
Why?
| | Thrombosis | 3 | 2022 | 374 | 0.730 |
Why?
| | Patch-Clamp Techniques | 13 | 2019 | 287 | 0.710 |
Why?
| | Cognition | 3 | 2019 | 1172 | 0.680 |
Why?
| | Sex Factors | 11 | 2024 | 2055 | 0.680 |
Why?
| | Excitatory Postsynaptic Potentials | 3 | 2016 | 123 | 0.670 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 4 | 2020 | 219 | 0.650 |
Why?
| | Neuronal Plasticity | 8 | 2023 | 296 | 0.650 |
Why?
| | Cerebellum | 4 | 2011 | 218 | 0.650 |
Why?
| | Pregnanolone | 2 | 2011 | 38 | 0.630 |
Why?
| | Brain-Derived Neurotrophic Factor | 4 | 2019 | 136 | 0.620 |
Why?
| | Potassium Channels | 8 | 2003 | 148 | 0.620 |
Why?
| | Estradiol | 5 | 2018 | 525 | 0.610 |
Why?
| | Nogo Proteins | 1 | 2019 | 10 | 0.610 |
Why?
| | Neural Inhibition | 3 | 2024 | 176 | 0.560 |
Why?
| | Nerve Regeneration | 1 | 2018 | 57 | 0.560 |
Why?
| | Adult Stem Cells | 1 | 2018 | 40 | 0.560 |
Why?
| | Guideline Adherence | 1 | 2022 | 551 | 0.530 |
Why?
| | Long-Term Synaptic Depression | 2 | 2018 | 55 | 0.530 |
Why?
| | Cognitive Dysfunction | 2 | 2019 | 388 | 0.530 |
Why?
| | Estrogens | 5 | 2013 | 368 | 0.520 |
Why?
| | Nervous System Diseases | 1 | 2019 | 272 | 0.510 |
Why?
| | Cerebrovascular Disorders | 2 | 2024 | 96 | 0.500 |
Why?
| | Neurogenesis | 1 | 2018 | 150 | 0.500 |
Why?
| | Clotrimazole | 2 | 2013 | 3 | 0.500 |
Why?
| | Neural Stem Cells | 1 | 2018 | 156 | 0.500 |
Why?
| | Mice, Knockout | 11 | 2021 | 3010 | 0.490 |
Why?
| | Aging | 3 | 2019 | 1852 | 0.490 |
Why?
| | Female | 44 | 2025 | 73713 | 0.490 |
Why?
| | Sirtuin 2 | 1 | 2015 | 24 | 0.470 |
Why?
| | Microglia | 5 | 2018 | 250 | 0.470 |
Why?
| | Emergency Medical Services | 1 | 2022 | 560 | 0.470 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 500 | 0.470 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2018 | 431 | 0.450 |
Why?
| | Oxygen | 4 | 2012 | 957 | 0.440 |
Why?
| | Cell Culture Techniques | 3 | 2013 | 364 | 0.440 |
Why?
| | Tissue Plasminogen Activator | 3 | 2022 | 230 | 0.440 |
Why?
| | Cell Hypoxia | 4 | 2013 | 227 | 0.440 |
Why?
| | Animal Experimentation | 1 | 2014 | 7 | 0.430 |
Why?
| | Kynurenine | 2 | 2025 | 114 | 0.420 |
Why?
| | Naltrexone | 1 | 2015 | 99 | 0.420 |
Why?
| | Models, Animal | 2 | 2013 | 392 | 0.420 |
Why?
| | Inhibitory Postsynaptic Potentials | 2 | 2011 | 45 | 0.420 |
Why?
| | Rats | 18 | 2023 | 5565 | 0.400 |
Why?
| | Cerebral Cortex | 3 | 2021 | 444 | 0.400 |
Why?
| | Potassium Channels, Voltage-Gated | 2 | 2003 | 50 | 0.390 |
Why?
| | Ion Channels | 4 | 2004 | 127 | 0.380 |
Why?
| | Peptides | 3 | 2023 | 982 | 0.370 |
Why?
| | Magnetic Fields | 3 | 2022 | 24 | 0.350 |
Why?
| | Synapses | 4 | 2021 | 420 | 0.330 |
Why?
| | Hydrogen Peroxide | 4 | 2020 | 332 | 0.330 |
Why?
| | Memory | 3 | 2023 | 255 | 0.330 |
Why?
| | Oxidative Stress | 7 | 2020 | 1319 | 0.320 |
Why?
| | Action Potentials | 7 | 2022 | 484 | 0.320 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 3 | 2014 | 24 | 0.320 |
Why?
| | Progesterone | 3 | 2010 | 257 | 0.310 |
Why?
| | Dexmedetomidine | 3 | 2014 | 40 | 0.310 |
Why?
| | Age Factors | 5 | 2021 | 3262 | 0.300 |
Why?
| | Rats, Sprague-Dawley | 9 | 2023 | 2472 | 0.290 |
Why?
| | Calcium Channels, T-Type | 2 | 2022 | 96 | 0.290 |
Why?
| | Cells, Cultured | 10 | 2018 | 4159 | 0.290 |
Why?
| | Immunohistochemistry | 7 | 2016 | 1727 | 0.290 |
Why?
| | Drug Delivery Systems | 2 | 2022 | 357 | 0.290 |
Why?
| | Ion Channel Gating | 6 | 2004 | 90 | 0.290 |
Why?
| | Glucose | 7 | 2014 | 1032 | 0.290 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2014 | 1101 | 0.280 |
Why?
| | NAD | 2 | 1999 | 77 | 0.280 |
Why?
| | Sepsis | 3 | 2019 | 603 | 0.270 |
Why?
| | HEK293 Cells | 3 | 2020 | 730 | 0.270 |
Why?
| | Humans | 36 | 2025 | 138201 | 0.270 |
Why?
| | Memory Disorders | 2 | 2019 | 171 | 0.270 |
Why?
| | Time Factors | 12 | 2025 | 6848 | 0.260 |
Why?
| | Brain Infarction | 3 | 2016 | 23 | 0.260 |
Why?
| | Tryptophan | 2 | 2025 | 183 | 0.250 |
Why?
| | Colloids | 2 | 2017 | 60 | 0.250 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2019 | 2027 | 0.250 |
Why?
| | Dihydrotestosterone | 5 | 2013 | 44 | 0.240 |
Why?
| | Protective Agents | 2 | 2019 | 42 | 0.230 |
Why?
| | Military Personnel | 2 | 2023 | 544 | 0.230 |
Why?
| | Paraplegia | 2 | 2015 | 60 | 0.210 |
Why?
| | Olfactory Receptor Neurons | 1 | 2004 | 41 | 0.210 |
Why?
| | Myelin Proteins | 3 | 2016 | 45 | 0.210 |
Why?
| | GABAergic Neurons | 1 | 2024 | 35 | 0.210 |
Why?
| | Receptors, Adrenergic, alpha-2 | 2 | 2013 | 10 | 0.210 |
Why?
| | Epoxide Hydrolases | 2 | 2013 | 13 | 0.210 |
Why?
| | Oxidants | 2 | 2020 | 112 | 0.210 |
Why?
| | Glycosaminoglycans | 1 | 2023 | 82 | 0.200 |
Why?
| | Calmodulin | 2 | 2019 | 73 | 0.200 |
Why?
| | Smell | 1 | 2004 | 118 | 0.200 |
Why?
| | Spinocerebellar Degenerations | 1 | 2003 | 7 | 0.200 |
Why?
| | Potassium Channels, Calcium-Activated | 4 | 2004 | 11 | 0.200 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2023 | 30 | 0.200 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 2 | 2013 | 50 | 0.200 |
Why?
| | Orchiectomy | 3 | 2013 | 75 | 0.200 |
Why?
| | Spinal Cord Ischemia | 2 | 2013 | 57 | 0.200 |
Why?
| | Corpus Striatum | 4 | 2016 | 175 | 0.200 |
Why?
| | Amyloid beta-Protein Precursor | 1 | 2023 | 66 | 0.200 |
Why?
| | Pneumonia | 2 | 2021 | 640 | 0.190 |
Why?
| | Blood-Brain Barrier | 2 | 2022 | 138 | 0.190 |
Why?
| | Behavior, Animal | 3 | 2018 | 509 | 0.190 |
Why?
| | Spinal Cord | 3 | 2014 | 373 | 0.190 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2023 | 79 | 0.190 |
Why?
| | Cerebrovascular Circulation | 1 | 2024 | 264 | 0.190 |
Why?
| | Primary Cell Culture | 2 | 2013 | 172 | 0.190 |
Why?
| | Heparitin Sulfate | 2 | 2019 | 46 | 0.190 |
Why?
| | Cerebral Infarction | 1 | 2022 | 48 | 0.190 |
Why?
| | Emergency Medical Dispatch | 1 | 2022 | 6 | 0.190 |
Why?
| | Metabolomics | 2 | 2024 | 686 | 0.190 |
Why?
| | Myelin Sheath | 3 | 2023 | 166 | 0.190 |
Why?
| | Plasminogen | 1 | 2021 | 30 | 0.180 |
Why?
| | Information Systems | 1 | 2022 | 60 | 0.180 |
Why?
| | Phosphorylation | 4 | 2023 | 1761 | 0.180 |
Why?
| | Receptors, Androgen | 3 | 2013 | 149 | 0.180 |
Why?
| | Benzimidazoles | 2 | 2014 | 174 | 0.180 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 325 | 0.180 |
Why?
| | Organ Culture Techniques | 1 | 2021 | 156 | 0.180 |
Why?
| | Heroin | 1 | 2021 | 31 | 0.180 |
Why?
| | Blotting, Western | 5 | 2012 | 1224 | 0.180 |
Why?
| | Islets of Langerhans | 2 | 1997 | 793 | 0.170 |
Why?
| | Spinal Cord Injuries | 2 | 2015 | 229 | 0.170 |
Why?
| | Cell Survival | 6 | 2020 | 1128 | 0.170 |
Why?
| | Eclampsia | 1 | 2020 | 4 | 0.170 |
Why?
| | Encephalitis | 2 | 2014 | 136 | 0.170 |
Why?
| | Presynaptic Terminals | 1 | 2021 | 88 | 0.170 |
Why?
| | Metabolome | 1 | 2024 | 351 | 0.170 |
Why?
| | Insulinoma | 2 | 1997 | 27 | 0.170 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2017 | 195 | 0.170 |
Why?
| | Extinction, Psychological | 1 | 2021 | 88 | 0.170 |
Why?
| | Amyloid beta-Peptides | 1 | 2023 | 219 | 0.170 |
Why?
| | Cell-Derived Microparticles | 1 | 2021 | 72 | 0.170 |
Why?
| | Adaptation, Physiological | 1 | 2004 | 553 | 0.160 |
Why?
| | Fibrinolysis | 2 | 2021 | 145 | 0.160 |
Why?
| | Thalamus | 1 | 2021 | 115 | 0.160 |
Why?
| | Death-Associated Protein Kinases | 1 | 2020 | 10 | 0.160 |
Why?
| | Cell Membrane | 2 | 2003 | 713 | 0.160 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 24 | 0.160 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 980 | 0.160 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 60 | 0.160 |
Why?
| | Inhibitory Concentration 50 | 1 | 2019 | 88 | 0.160 |
Why?
| | Intravital Microscopy | 1 | 2019 | 24 | 0.160 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2020 | 60 | 0.160 |
Why?
| | Insulin | 3 | 1999 | 2405 | 0.160 |
Why?
| | Optical Imaging | 1 | 2019 | 62 | 0.150 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2019 | 73 | 0.150 |
Why?
| | Models, Theoretical | 1 | 2023 | 581 | 0.150 |
Why?
| | Extracellular Vesicles | 1 | 2021 | 147 | 0.150 |
Why?
| | Fibrinolytic Agents | 1 | 2022 | 275 | 0.150 |
Why?
| | Axons | 2 | 2018 | 195 | 0.150 |
Why?
| | Cofilin 1 | 1 | 2018 | 5 | 0.150 |
Why?
| | Mice, Transgenic | 6 | 2016 | 2166 | 0.150 |
Why?
| | Mutagenesis | 1 | 2019 | 183 | 0.150 |
Why?
| | Oligosaccharides | 1 | 2019 | 59 | 0.150 |
Why?
| | Drug Design | 1 | 2019 | 165 | 0.150 |
Why?
| | Calcineurin | 1 | 2019 | 107 | 0.150 |
Why?
| | Protein Aggregation, Pathological | 1 | 2018 | 21 | 0.150 |
Why?
| | Nerve Net | 1 | 2021 | 268 | 0.150 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 568 | 0.140 |
Why?
| | Thalamic Nuclei | 1 | 2018 | 10 | 0.140 |
Why?
| | Holoenzymes | 1 | 2018 | 24 | 0.140 |
Why?
| | Pre-Eclampsia | 1 | 2020 | 192 | 0.140 |
Why?
| | Biomedical Research | 1 | 2024 | 696 | 0.140 |
Why?
| | Interleukin-10 | 3 | 2015 | 304 | 0.140 |
Why?
| | Lateral Ventricles | 1 | 2018 | 34 | 0.140 |
Why?
| | Myelin Proteolipid Protein | 1 | 2018 | 61 | 0.140 |
Why?
| | Molecular Dynamics Simulation | 1 | 2019 | 243 | 0.140 |
Why?
| | Intracranial Arterial Diseases | 1 | 2017 | 8 | 0.140 |
Why?
| | Membrane Proteins | 2 | 2021 | 1152 | 0.140 |
Why?
| | Alloxan | 1 | 1997 | 4 | 0.140 |
Why?
| | Heparin | 1 | 2019 | 251 | 0.140 |
Why?
| | Receptors, AMPA | 2 | 2018 | 140 | 0.130 |
Why?
| | Mitochondria | 2 | 2021 | 951 | 0.130 |
Why?
| | Glutathione | 1 | 1999 | 356 | 0.130 |
Why?
| | Receptors, Glutamate | 1 | 2016 | 26 | 0.130 |
Why?
| | Cerebral Arteries | 1 | 2017 | 58 | 0.130 |
Why?
| | Dementia | 1 | 2020 | 264 | 0.130 |
Why?
| | Gene Knockdown Techniques | 2 | 2020 | 328 | 0.130 |
Why?
| | Leukoencephalopathies | 1 | 2016 | 19 | 0.130 |
Why?
| | Actins | 1 | 2018 | 419 | 0.120 |
Why?
| | Pericytes | 1 | 2016 | 34 | 0.120 |
Why?
| | Cations | 3 | 2003 | 85 | 0.120 |
Why?
| | Inflammation | 4 | 2021 | 2843 | 0.120 |
Why?
| | Spleen | 3 | 2015 | 521 | 0.120 |
Why?
| | Furans | 1 | 2015 | 24 | 0.120 |
Why?
| | Collagen Type I | 1 | 2016 | 138 | 0.120 |
Why?
| | Cell Communication | 2 | 2016 | 315 | 0.120 |
Why?
| | Tretinoin | 1 | 2016 | 122 | 0.120 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2013 | 349 | 0.120 |
Why?
| | Transfection | 2 | 2016 | 941 | 0.120 |
Why?
| | Magnetic Resonance Angiography | 1 | 2017 | 243 | 0.120 |
Why?
| | Brain Concussion | 1 | 2023 | 579 | 0.120 |
Why?
| | Arginase | 1 | 2015 | 28 | 0.120 |
Why?
| | Interleukin-1beta | 2 | 2014 | 374 | 0.110 |
Why?
| | Membrane Potentials | 5 | 1999 | 281 | 0.110 |
Why?
| | Calbindins | 1 | 2014 | 6 | 0.110 |
Why?
| | Neutrophil Activation | 1 | 2015 | 84 | 0.110 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 30 | 0.110 |
Why?
| | Dizocilpine Maleate | 1 | 2014 | 23 | 0.110 |
Why?
| | Calcium Channel Agonists | 1 | 2014 | 12 | 0.110 |
Why?
| | Quinolines | 1 | 2015 | 153 | 0.110 |
Why?
| | Trauma, Nervous System | 1 | 2014 | 3 | 0.110 |
Why?
| | Toll-Like Receptor 4 | 2 | 2013 | 272 | 0.110 |
Why?
| | Tissue Culture Techniques | 1 | 2014 | 82 | 0.110 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2014 | 103 | 0.110 |
Why?
| | Microinjections | 2 | 2011 | 86 | 0.110 |
Why?
| | Mutation | 2 | 2020 | 3993 | 0.110 |
Why?
| | Aged | 6 | 2025 | 24134 | 0.110 |
Why?
| | Lentivirus | 2 | 2011 | 59 | 0.110 |
Why?
| | Nerve Tissue Proteins | 2 | 2016 | 597 | 0.110 |
Why?
| | Analysis of Variance | 3 | 2015 | 1314 | 0.110 |
Why?
| | Aortic Diseases | 1 | 2015 | 119 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2022 | 1545 | 0.100 |
Why?
| | CD40 Antigens | 1 | 2014 | 89 | 0.100 |
Why?
| | Electroencephalography | 1 | 2016 | 440 | 0.100 |
Why?
| | Cross Infection | 1 | 2016 | 250 | 0.100 |
Why?
| | Arachidonic Acids | 1 | 2013 | 64 | 0.100 |
Why?
| | Body Temperature | 1 | 2014 | 222 | 0.100 |
Why?
| | Immunophenotyping | 1 | 2014 | 326 | 0.100 |
Why?
| | bcl-2-Associated X Protein | 1 | 2013 | 56 | 0.100 |
Why?
| | Embryo, Mammalian | 1 | 2013 | 235 | 0.100 |
Why?
| | Piperidines | 1 | 2014 | 212 | 0.100 |
Why?
| | Immune Tolerance | 1 | 2015 | 366 | 0.100 |
Why?
| | Glomerular Filtration Barrier | 1 | 2012 | 1 | 0.100 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2013 | 203 | 0.100 |
Why?
| | Ovariectomy | 3 | 2025 | 155 | 0.100 |
Why?
| | Polymerase Chain Reaction | 3 | 2012 | 1049 | 0.100 |
Why?
| | Testosterone | 3 | 2010 | 401 | 0.090 |
Why?
| | RNA, Small Interfering | 2 | 2011 | 621 | 0.090 |
Why?
| | Endothelium | 1 | 2012 | 125 | 0.090 |
Why?
| | Microscopy, Immunoelectron | 1 | 2011 | 45 | 0.090 |
Why?
| | Iraq War, 2003-2011 | 2 | 2023 | 128 | 0.090 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2011 | 68 | 0.090 |
Why?
| | Acute Lung Injury | 1 | 2014 | 286 | 0.090 |
Why?
| | Afghan Campaign 2001- | 2 | 2023 | 130 | 0.090 |
Why?
| | Up-Regulation | 2 | 2025 | 846 | 0.090 |
Why?
| | Culture Media | 1 | 2011 | 163 | 0.090 |
Why?
| | Pyramidal Cells | 1 | 2011 | 73 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2022 | 10914 | 0.080 |
Why?
| | Biomarkers | 2 | 2025 | 4101 | 0.080 |
Why?
| | Retrospective Studies | 7 | 2023 | 15842 | 0.080 |
Why?
| | United States | 3 | 2023 | 14983 | 0.080 |
Why?
| | Child | 4 | 2019 | 21862 | 0.080 |
Why?
| | Isoflurane | 1 | 2010 | 32 | 0.080 |
Why?
| | Anesthetics, Inhalation | 1 | 2010 | 36 | 0.080 |
Why?
| | Cell Line | 5 | 2012 | 2865 | 0.080 |
Why?
| | Aged, 80 and over | 4 | 2025 | 7683 | 0.080 |
Why?
| | Cell Movement | 1 | 2014 | 971 | 0.080 |
Why?
| | Genetic Vectors | 1 | 2011 | 335 | 0.080 |
Why?
| | RNA, Messenger | 4 | 2018 | 2808 | 0.080 |
Why?
| | Disease Progression | 1 | 2017 | 2734 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 2 | 2011 | 662 | 0.080 |
Why?
| | Ischemic Attack, Transient | 1 | 2010 | 67 | 0.080 |
Why?
| | Motor Activity | 2 | 2011 | 711 | 0.080 |
Why?
| | In Vitro Techniques | 1 | 2011 | 1089 | 0.080 |
Why?
| | Neutrophils | 1 | 2015 | 1273 | 0.080 |
Why?
| | Pregnancy | 3 | 2020 | 6792 | 0.070 |
Why?
| | Oligodendroglia | 2 | 2023 | 178 | 0.070 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2013 | 873 | 0.070 |
Why?
| | Animals, Newborn | 2 | 2023 | 847 | 0.070 |
Why?
| | Risk Assessment | 3 | 2025 | 3452 | 0.070 |
Why?
| | Kidney | 2 | 2012 | 1471 | 0.070 |
Why?
| | Apoptosis | 3 | 2016 | 2556 | 0.070 |
Why?
| | In Situ Nick-End Labeling | 1 | 2006 | 125 | 0.060 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2011 | 719 | 0.060 |
Why?
| | Menopause | 1 | 2010 | 326 | 0.060 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 806 | 0.060 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 38 | 0.060 |
Why?
| | Muscle Denervation | 2 | 2002 | 9 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2010 | 407 | 0.060 |
Why?
| | B-Lymphocytes | 1 | 2011 | 856 | 0.060 |
Why?
| | Tumor Cells, Cultured | 2 | 1997 | 947 | 0.060 |
Why?
| | Cyclic Nucleotide-Gated Cation Channels | 1 | 2004 | 15 | 0.060 |
Why?
| | Electrophysiology | 3 | 2003 | 217 | 0.050 |
Why?
| | Decorin | 1 | 2023 | 7 | 0.050 |
Why?
| | Hospital Mortality | 2 | 2021 | 911 | 0.050 |
Why?
| | Middle Aged | 5 | 2025 | 33711 | 0.050 |
Why?
| | Infarction | 1 | 2023 | 11 | 0.050 |
Why?
| | Chondroitin Sulfates | 1 | 2023 | 31 | 0.050 |
Why?
| | Cyclic AMP | 1 | 2004 | 219 | 0.050 |
Why?
| | Kv1.1 Potassium Channel | 1 | 2003 | 8 | 0.050 |
Why?
| | Genes, Lethal | 1 | 2003 | 30 | 0.050 |
Why?
| | Carbonic Anhydrases | 1 | 2003 | 13 | 0.050 |
Why?
| | Acetazolamide | 1 | 2003 | 24 | 0.050 |
Why?
| | Shal Potassium Channels | 1 | 2003 | 7 | 0.050 |
Why?
| | Fasciculation | 1 | 2002 | 2 | 0.050 |
Why?
| | Iraq | 1 | 2023 | 55 | 0.050 |
Why?
| | Rats, Wistar | 2 | 2017 | 448 | 0.050 |
Why?
| | Afghanistan | 1 | 2023 | 71 | 0.050 |
Why?
| | Databases, Factual | 2 | 2021 | 1391 | 0.050 |
Why?
| | Spatial Memory | 1 | 2022 | 26 | 0.050 |
Why?
| | Risk Factors | 3 | 2025 | 10366 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 155 | 0.050 |
Why?
| | Models, Neurological | 1 | 2004 | 248 | 0.050 |
Why?
| | Tolbutamide | 2 | 1999 | 5 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2024 | 451 | 0.050 |
Why?
| | Fibrin Clot Lysis Time | 1 | 2021 | 9 | 0.050 |
Why?
| | Muscular Diseases | 1 | 2002 | 112 | 0.050 |
Why?
| | Muscle, Skeletal | 2 | 2002 | 1739 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2014 | 442 | 0.050 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 2 | 2011 | 53 | 0.040 |
Why?
| | Self Administration | 1 | 2021 | 126 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2023 | 202 | 0.040 |
Why?
| | Aorta, Thoracic | 2 | 2013 | 272 | 0.040 |
Why?
| | Adoptive Transfer | 2 | 2011 | 221 | 0.040 |
Why?
| | Synaptic Transmission | 1 | 2003 | 291 | 0.040 |
Why?
| | Tumor Necrosis Factors | 1 | 2020 | 11 | 0.040 |
Why?
| | Swine | 1 | 2023 | 798 | 0.040 |
Why?
| | Inflammation Mediators | 2 | 2013 | 511 | 0.040 |
Why?
| | Neurotoxins | 1 | 2020 | 28 | 0.040 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2001 | 216 | 0.040 |
Why?
| | Nucleus Accumbens | 1 | 2021 | 149 | 0.040 |
Why?
| | Air Ambulances | 1 | 2020 | 32 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2020 | 240 | 0.040 |
Why?
| | Stress, Physiological | 1 | 2003 | 454 | 0.040 |
Why?
| | Dendritic Spines | 1 | 2020 | 66 | 0.040 |
Why?
| | Thapsigargin | 1 | 1999 | 20 | 0.040 |
Why?
| | Cesium | 1 | 1999 | 20 | 0.040 |
Why?
| | Ion Transport | 1 | 1999 | 60 | 0.040 |
Why?
| | Lymph Nodes | 2 | 2011 | 495 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2003 | 1237 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 1102 | 0.040 |
Why?
| | Barium | 1 | 1997 | 26 | 0.030 |
Why?
| | Oligodendrocyte Precursor Cells | 1 | 2018 | 20 | 0.030 |
Why?
| | Glutamic Acid | 1 | 2020 | 248 | 0.030 |
Why?
| | Resuscitation | 1 | 2020 | 238 | 0.030 |
Why?
| | Thiourea | 1 | 1997 | 41 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2019 | 249 | 0.030 |
Why?
| | Magnesium | 1 | 1997 | 157 | 0.030 |
Why?
| | Free Radical Scavengers | 1 | 1997 | 87 | 0.030 |
Why?
| | Seizures | 1 | 2020 | 432 | 0.030 |
Why?
| | Kinetics | 2 | 1997 | 1641 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2018 | 276 | 0.030 |
Why?
| | Oligopeptides | 1 | 1999 | 272 | 0.030 |
Why?
| | Exons | 1 | 2018 | 355 | 0.030 |
Why?
| | Niacinamide | 1 | 1997 | 82 | 0.030 |
Why?
| | Inpatients | 1 | 2021 | 493 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2018 | 392 | 0.030 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2016 | 47 | 0.030 |
Why?
| | Protein Transport | 1 | 2018 | 440 | 0.030 |
Why?
| | Protein Domains | 1 | 2018 | 289 | 0.030 |
Why?
| | Heme Oxygenase-1 | 1 | 2016 | 64 | 0.030 |
Why?
| | Mice, Inbred ICR | 1 | 2016 | 119 | 0.030 |
Why?
| | Hypoxia | 2 | 2014 | 1121 | 0.030 |
Why?
| | Glutathione Transferase | 1 | 2016 | 102 | 0.030 |
Why?
| | Glucose Transporter Type 1 | 1 | 2016 | 48 | 0.030 |
Why?
| | Biological Transport | 1 | 2017 | 401 | 0.030 |
Why?
| | Cell Polarity | 1 | 1997 | 140 | 0.030 |
Why?
| | Stromal Cells | 1 | 2016 | 111 | 0.030 |
Why?
| | Cytokines | 2 | 2014 | 2080 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 786 | 0.030 |
Why?
| | Cysteine | 1 | 1997 | 203 | 0.030 |
Why?
| | Adult | 2 | 2021 | 38190 | 0.030 |
Why?
| | Estrogen Receptor alpha | 2 | 2010 | 145 | 0.030 |
Why?
| | Adolescent | 3 | 2021 | 21503 | 0.030 |
Why?
| | Functional Laterality | 1 | 2016 | 231 | 0.030 |
Why?
| | Receptors, Estrogen | 2 | 2012 | 439 | 0.030 |
Why?
| | Pharmaceutical Preparations | 1 | 2017 | 177 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 1997 | 486 | 0.030 |
Why?
| | Neurologic Examination | 1 | 2015 | 126 | 0.030 |
Why?
| | Blood Vessels | 1 | 2016 | 180 | 0.030 |
Why?
| | California | 1 | 2016 | 441 | 0.030 |
Why?
| | Nanostructures | 1 | 2016 | 109 | 0.030 |
Why?
| | T-Lymphocytes | 2 | 2015 | 1982 | 0.030 |
Why?
| | Colorado | 1 | 2025 | 4526 | 0.030 |
Why?
| | Hindlimb | 1 | 2015 | 133 | 0.030 |
Why?
| | Chronic Disease | 1 | 2021 | 1798 | 0.030 |
Why?
| | Locomotion | 1 | 2015 | 105 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 1997 | 625 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2014 | 191 | 0.030 |
Why?
| | Hematoxylin | 1 | 2013 | 8 | 0.030 |
Why?
| | Eosine Yellowish-(YS) | 1 | 2013 | 10 | 0.030 |
Why?
| | Fluoresceins | 1 | 2013 | 49 | 0.030 |
Why?
| | Constriction | 1 | 2013 | 47 | 0.030 |
Why?
| | Cohort Studies | 1 | 2024 | 5717 | 0.030 |
Why?
| | Arginine | 1 | 2015 | 260 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2003 | 2589 | 0.030 |
Why?
| | Chalcones | 1 | 2013 | 7 | 0.030 |
Why?
| | CREB-Binding Protein | 1 | 2013 | 33 | 0.030 |
Why?
| | Movement | 1 | 2016 | 282 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 2232 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1080 | 0.030 |
Why?
| | Ligation | 1 | 2013 | 93 | 0.030 |
Why?
| | Apamin | 2 | 2004 | 4 | 0.030 |
Why?
| | Mice, Inbred C3H | 1 | 2013 | 269 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1495 | 0.020 |
Why?
| | Hypoglycemic Agents | 2 | 1999 | 1302 | 0.020 |
Why?
| | Fluorescein-5-isothiocyanate | 1 | 2012 | 36 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 237 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2037 | 0.020 |
Why?
| | Fibronectins | 1 | 2012 | 132 | 0.020 |
Why?
| | Kidney Glomerulus | 1 | 2012 | 119 | 0.020 |
Why?
| | Proteins | 1 | 1997 | 1013 | 0.020 |
Why?
| | Lymphocyte Subsets | 1 | 2011 | 88 | 0.020 |
Why?
| | Receptors, CCR7 | 1 | 2011 | 32 | 0.020 |
Why?
| | Comorbidity | 1 | 2016 | 1645 | 0.020 |
Why?
| | Receptors, CCR5 | 1 | 2011 | 59 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2083 | 0.020 |
Why?
| | Hyaluronan Receptors | 1 | 2011 | 102 | 0.020 |
Why?
| | Mice, SCID | 1 | 2011 | 369 | 0.020 |
Why?
| | Blood | 1 | 2011 | 110 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2010 | 89 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2012 | 318 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2011 | 414 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 430 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2470 | 0.020 |
Why?
| | Aromatase | 1 | 2010 | 32 | 0.020 |
Why?
| | Kidney Cortex | 1 | 2010 | 26 | 0.020 |
Why?
| | Blood Urea Nitrogen | 1 | 2010 | 54 | 0.020 |
Why?
| | Acute-Phase Proteins | 1 | 2010 | 66 | 0.020 |
Why?
| | Aromatase Inhibitors | 1 | 2010 | 60 | 0.020 |
Why?
| | Lipocalins | 1 | 2010 | 36 | 0.020 |
Why?
| | Exploratory Behavior | 1 | 2010 | 89 | 0.020 |
Why?
| | Estrogen Receptor beta | 1 | 2010 | 41 | 0.020 |
Why?
| | Oncogene Proteins | 1 | 2010 | 57 | 0.020 |
Why?
| | Renal Circulation | 1 | 2010 | 65 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 883 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2013 | 474 | 0.020 |
Why?
| | Lipocalin-2 | 1 | 2010 | 79 | 0.020 |
Why?
| | Castration | 1 | 2009 | 14 | 0.020 |
Why?
| | Blood Chemical Analysis | 1 | 2010 | 110 | 0.020 |
Why?
| | Androgen Receptor Antagonists | 1 | 2009 | 35 | 0.020 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2010 | 207 | 0.020 |
Why?
| | Androgen Antagonists | 1 | 2009 | 93 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1245 | 0.020 |
Why?
| | Creatinine | 1 | 2010 | 487 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5160 | 0.020 |
Why?
| | Wound Healing | 1 | 2010 | 346 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 1197 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 740 | 0.020 |
Why?
| | Autoimmunity | 1 | 2011 | 901 | 0.010 |
Why?
| | Pediatrics | 1 | 2013 | 1073 | 0.010 |
Why?
| | Infant | 1 | 2018 | 9553 | 0.010 |
Why?
| | Young Adult | 1 | 2021 | 13298 | 0.010 |
Why?
| | Child, Preschool | 1 | 2018 | 11115 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 2004 | 320 | 0.010 |
Why?
| | Evoked Potentials | 1 | 2004 | 128 | 0.010 |
Why?
| | Blood Pressure | 1 | 2010 | 1730 | 0.010 |
Why?
| | COS Cells | 1 | 2003 | 183 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 2003 | 82 | 0.010 |
Why?
| | Myoblasts | 1 | 2003 | 82 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2003 | 272 | 0.010 |
Why?
| | Egtazic Acid | 1 | 2001 | 40 | 0.010 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2001 | 43 | 0.010 |
Why?
| | Enhancer Elements, Genetic | 1 | 2003 | 189 | 0.010 |
Why?
| | Cobalt | 1 | 2001 | 52 | 0.010 |
Why?
| | Chelating Agents | 1 | 2001 | 75 | 0.010 |
Why?
| | Potassium | 1 | 2001 | 145 | 0.010 |
Why?
| | Calcium Channels | 1 | 2001 | 155 | 0.010 |
Why?
| | Electromyography | 1 | 2002 | 393 | 0.010 |
Why?
| | Muscle Contraction | 1 | 2002 | 435 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 2180 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2925 | 0.010 |
Why?
| | Biotransformation | 1 | 1997 | 62 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2003 | 1458 | 0.010 |
Why?
| | Potassium Channel Blockers | 1 | 1996 | 42 | 0.010 |
Why?
| | Leptin | 1 | 1997 | 242 | 0.010 |
Why?
| | Xenopus laevis | 1 | 1996 | 106 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1996 | 339 | 0.010 |
Why?
| | Macromolecular Substances | 1 | 1996 | 227 | 0.010 |
Why?
| | Oocytes | 1 | 1996 | 178 | 0.010 |
Why?
| | DNA Primers | 1 | 1996 | 508 | 0.010 |
Why?
|
|
Herson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|